Disease of geese caused by a new herpesvirus

A goose flock farmed outdoors in south-eastern Queensland suffered an outbreak of peracute disease with high death rate (97%). Small button ulcers and large plaques overlying lymphocyte aggregates were present on the mucosa of the small intestine of affected birds. Small white foci of necrosis and focal haemorrhages were seen in the livers. Numerous intranuclear inclusion bodies were observed microscopically in hepatocytes and a herpesvirus which grew rapidly in chicken kidney cells was isolated from tissues. Duck virus enteritis (DVE) was suspected but DVE antiserums failed to neutralise the virus. Further serological studies with a limited range of known avian herpesviruses have failed to identify the virus. Experimental transmission resulted in high mortality in geese (100%), lower mortality in ducklings and nil mortality in chickens. Surveillance studies showed no evidence of infection in domestic and wild birds beyond the original farm and the infection appears not to have been established in the area. Wild ducks, which were frequent visitors to the farm dam, were considered the most likely source of the infection.     

Prevention of atrophic rhinitis in piglets by means of intranasal administration of a live non-AR-pathogenic Bordetella bronchiseptica vaccine

The effect of intranasal vaccination of piglets with live non-AR-pathogenic Bordetella bronchiseptica (BB-) against Atrophic Rhinitis (AR) was investigated in a preliminary investigation and in a field trial. In the preliminary investigation 2-day-old SPF piglets (n = 13) were vaccinated. Three weeks after vaccination, challenges were carried out by means of a spray with an AR-pathogenic B (BB+) or an AR-pathogenic Pasteurella multocida (PM+) broth-culture. Four weeks later the piglets were necropsied and examined for atrophy of the ventral conchae (AVC). In contrast with the non-vaccinated SPF piglets, the vaccinated piglets showed a strong and significant reduction of AVC, after both BB+ and PM+ challenge. In the field trial three groups were formed by drawing lots: ten litters (82 piglets) were vaccinated; ten litters (92 piglets) formed the control group and 11 litters (104 piglets) were treated with a placebo. The litters were spread over two units. In unit 1 AR and PM+ were demonstrated incidentally, in unit 2, however, persistently. BB+ was isolated equally frequently in both units. Clinical and bacteriological examinations were done in piglets of 3, 6 and 8 weeks of age. Necropsy examinations was carried out in 41 piglets of 8 weeks of age, chosen randomly by drawing lots. In spite of a second vaccination at the age of 3 weeks, BB- was not well established; this was possibly caused by maternal BB antibodies. In the control and placebo groups PM+ was isolated earlier and more frequently than BB+. It appeared that AVC was correlated more strongly with PM+ than with BB+ infection in the field trial. The percentage of piglets with Brachygnathia superior (BS) at the age of 8 weeks indicated the AR situation in the herd. Although a significant reduction of AVC was determined in unit 2, it was not sufficient to indicate that this method of intranasal vaccination is useful in the prevention of AR in practice.     

Therapeutic efficacy of doxycycline hyclate in experimental Escherichia coli infection in broilers

Treatment of experimentally induced colibacillosis in broilers with doxycycline hyclate through the drinking water was just effective at a dose of 200 mg/kg body weight (1000 ppm). The achieved therapeutic effects were similar to those of tetracycline at the same dose and of flumequine at a dose of 19 mg/kg body weight (100 ppm).     

Comparison of the sensitivity of in vitro and in vivo tests for detection of the presence of a bovine viral diarrhoea virus type 1 strain

Veterinary vaccines are usually tested for the absence of contaminants. However, the quality control does not always imply that vaccines are not contaminated as, for example, illustrated by the bovine herpes virus 1 (BHV1) vaccine used in The Netherlands in 1999 that contained a small amount of bovine viral diarrhoea virus (BVDV1). Thousands of cows were vaccinated with BHV1 vaccine batches, and the question arose as to whether these small amounts of BVDV1, most likely not detected with in vitro tests, could have infected cattle. More in general, the question was whether the outcome of the in vitro tests, i.e. the in vitro infectivity, was indicative for the infectivity for cattle, i.e. the in vivo infectivity. We therefore carried out in vitro experiments to determine the sensitivity of a BVDV1 isolation assay. In addition, we performed two animal experiments, in which we estimated the lowest dose needed to infect calves with BVDV1. We extrapolated the experimental in vitro and in vivo results from a tissue culture infectious dose (TCID50) to a cattle infectious dose (CID50). We observed a partial response in the calves inoculated with this dose: four out of six calves turned out to be infected. In the tissue culture test, all 20 samples tested negative. The response in vivo, however, was not significantly higher than the in vitro response, which implies that no difference in susceptibility was observed between the animal test and the tissue culture test. Based on the results in our experiments, some cattle may have been infected with BVDV1 after the application of the contaminated BHV1 vaccine during the vaccination campaign. The question remains that how many cattle received contaminated vaccine, and became infected with BVDV1.     

Isolation and characterization of a new compound from Prunus mume fruit that inhibits cancer cells

An active compound that inhibits cancer cells was isolated from the fruit of Prunus mume, and its structure and in vitro activities were characterized. The n-hexane fraction obtained from methanol extracts exhibited the strongest inhibitory effect on the growth of cancer cells. From the n-hexane fraction, a new compound named B-1 was purified through preparative thin-layer chromatography, ODS column chromatography, and reverse phase high-performance liquid chromatography and its structure was analyzed by fast atom bombardment mass spectrometry and 1H and 13C NMR. The molecular formula of B-1 was C19H22O6 {2-hydroxy-1-[(7-hydroxy-2-oxo-2H-chromen-6-yl)methyl]-2-methylpropyl-(2Z)-3-methyl-but-e-enoate:prunate}, and the IC50 value was in the range of 39-58 microg/mL in descending order of the cancer cell lines Hep-2, SW-156, HEC-1-B, and SK-OV-3. B-1 exhibited 81-96% inhibition at a concentration level of 100 microg/mL against all cells, based on an 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide assay. However, B-1 showed little effect against normal cells with only 23% or less growth inhibition at 100 microg/mL. Thus, B-1 has a highly specific inhibitory effect against cancer cells but little effect against normal cells. When the cancer cell lines Hep-2 and SK-OV-3 were incubated with B-1 for 72 h, most of the tested cells suffered strong growth inhibition. The compound has the potential to be developed as a nutraceutical.